VolitionRx (NYSE:VNRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research note published on Friday morning. The firm issued a sell rating on the stock.

Separately, Cantor Fitzgerald restated an overweight rating and set a $2.50 target price on shares of VolitionRx in a research note on Thursday, May 16th.

VolitionRx Stock Performance

Shares of VolitionRx stock traded up $0.03 on Friday, reaching $0.60. 169,466 shares of the stock were exchanged, compared to its average volume of 176,403. The firm has a market cap of $49.51 million, a PE ratio of -1.30 and a beta of 1.13. The firm’s 50 day moving average is $0.64 and its 200-day moving average is $0.78. VolitionRx has a one year low of $0.43 and a one year high of $1.38.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.